Best of ASCO - 2014 Annual Meeting

 

Welcome

Soft Tissue

Sarcoma

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A matched cohort study of adjuvant radiochemotherapy versus radiotherapy alone in soft tissue sarcoma patients.

Daniela Greto

e23554

A multicenter phase II study of pazopanib in patients with unresectable or recurrent dermatofibrosarcoma protuberans (DFSP).

Julie Delyon

11557

A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).

Todd Michael Bauer

11514

A phase I trial of pomalidomide in combination with liposomal doxorubicin in the treatment of advanced or refractory Kaposi sarcoma in individuals with or without HIV.

Ramya Ramaswami

TPS11586

A phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.

Mark Agulnik

11550

A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma.

Ciara Marie Kelly

11516

A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS).

Breelyn A. Wilky

11547

A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.

Richard F. Riedel

11505

Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.

Patrick Schoffski

11540

Activity of single-agent PD-1 inhibitor (PD-1i) therapy in advanced sarcoma: A single-center retrospective analysis.

Dionisia Marie Quiroga

e23541

Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial.

Yihebali Chi

11503

Anti CXCR4 antibody combined with activated and expanded natural killer cells for sarcoma immunotherapy.

Maria Vela

11541

Apatinib in advanced alveolar soft part sarcoma: Evidence of efficacy and safety.

Li Min

e23521

Association of multimodality treatment (MT) with improved overall survival (OS) in patients (pts) with advanced/metastastic soft tissue sarcoma (a/m STS).

Philipp Ivanyi

e23566

CDKN2A deletion as a prognostic marker: A clinico-genomic analysis of sarcoma patients.

Nam Bui

11543

Characteristics and clinical outcomes of French patients diagnosed with advanced soft tissue sarcoma (aSTS) in real-life setting: Data from the European sarcoma biological and clinical data banking (ESBCB).

Jean-Yves Blay

11548

Characterization of tumor microenvironment in extraskeletal myxoid chondrosarcoma (EMC).

Valentina Indio

11561

Clinical and pathological analysis of eleven adult patients with inflammatory myofibroblastic tumor.

Xin Liu

11545

Clinical experience with combination chemo-/immunotherapy using trabectedin and nivolumab for advanced soft tissue sarcoma.

Sant P. Chawla

e23568

Clinical experience with dermatofibrosarcoma protuberans (DFSP) in a diverse ethnic population.

Ah-Reum Jeong

e23531

Clinicopathologic features and survival outcomes of sarcomatoid carcinoma presenting as cancer of unknown primary.

Ryan Huey

e23565

Combination of CDK and Bcl-2 inhibitors in the treatment of soft-tissue sarcomas.

Xavier Garcia del Muro

11582

Compared descriptive analysis of immunologic landscape in soft tissue sarcoma and GIST.

Armelle Dufresne

11517

Decreased lymphocyte count at diagnosis as a marker for worse outcome in localized sarcoma.

Nam Bui

e23537

DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group.

Maud Toulmonde

11501

Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).

Vinod Ravi

e23570

Discovery and characterization of novel, recurrent, targetable ALK fusions in leiomyosarcoma.

Lara Emily Davis

11563

Dose dense paclitaxel in patients with advanced liposarcoma: Subgroup analysis from a phase II trial.

Fernando Aldaco

e23557

Doxorubicin (D), gemcitabine (G), ifosfamide (I) and the EZH2 inhibitor EPZ-011989 in epithelioid sarcoma (ES): A comparison of different regimens in a patient-derived xenograft (PDX) model.

Nadia Zaffaroni

11578

Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).

Lorenzo D'Ambrosio

11574

Early metabolic response as predictor for treatment outcome of pazopanib in patients with metastatic soft tissue sarcomas (the PREDICT study).

Winette T.A. Van Der Graaf

11555

Effect of JS001, a monoclonal antibody targeting programed death-1 (PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma: Results from a phase 1 trial.

Sheng Yang

11572

Efficacy and safety of apatinib in advanced soft tissue sarcoma: A multi-center, open-label phase II clinical trial.

Wenxi Yu

11546

Efficacy and safety of apatinib in osteosarcoma lung metastasis.

Qianrong Wang

e23527

Efficacy comparison of pazopanib and trabectedin vs standard chemotherapy in second line treatment of patients with metastatic soft tissue sarcomas: Experience from countries with limited resources.

Anes Pasic

e23555

FAP-related desmoid tumours treated with low dose chemotherapy: Results from a multicentre retrospective analysis.

Bruno Vincenzi

11556

Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).

William D. Tap

11502

First prospective observational study in diffuse-type tenosynovial giant cell tumors.

Monique Mastboom

11560

Frequency of genomic biomarkers of response to immunotherapy in sarcoma.

Sally E. Trabucco

11579

Gemcitabine re-challenge in metastatic soft tissue sarcoma: A therapeutic option for selected patients.

Ana Sebio

11559

Genomic alterations and clinical outcomes in patients with advanced liposarcoma.

Edward S. Kim

e23558

Genomic alterations in the homologous recombination pathway in soft-tissue sarcomas.

Nathan David Seligson

11549

Genomic amplification of CDK4 in dedifferentiated liposarcomas as a predictive biomarker for microtubule disrupting agents.

Bryce Demoret

11581

Genomic and proteomic analysis of patient tumors for molecular target selection.

Shiva Sreenath Andrali

e23567

Genomic subtypes of angiosarcoma: A comprehensive genomic profiling (CGP) study.

Vinod Ravi

11576

Identification of an actionable mutation of KIT in extraskeletal myxoid chondrosarcoma (EMC).

Milena Urbini

e23547

Identification of histone deacetylase 2 (HDAC2) as a novel target for MDM2 directed therapies in dedifferentiated liposarcoma.

Colin W Stets

11583

Identification of leiomyosarcoma circulating tumor DNA through ultra-low passage whole genome sequencing and correlation with tumor burden: A pilot experience.

Matthew Louis Hemming

11565

Identification of novel intra-genic deletions of CTNNB1 gene in WT desmoid-type fibromatosis.

Milena Urbini

11577

Immune signature in sarcoma with prognostic and predictive implications.

Shailaja KS Raj

11584

IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypes—Results of the phase I part.

Javier Martin Broto

11515

Impact of chemotherapy on survival in locally advanced and metastatic soft tissue sarcoma.

Mark Ashamalla

e23536

Impact of hospital volume on patterns of care and outcomes in soft tissue sarcoma.

James Don Murphy

e23550

Impact of pathological stratification of advanced well differentiated/dedifferentiated (WD/DD) liposarcoma (LPS) on the response to trabectedin (T).

Roberta Sanfilippo

11566

Improved survival in AYAs with NRSTS treated at specialized cancer centers in California.

Elysia Marie Alvarez

e23551

Incidence of soft tissue sarcoma in China.

Rongshou Zheng

e23560

Inferior vena cava leiomyosarcoma: A single-institution experience.

Brittany Siontis

e23556

Influence of age and histologic subtype in outcome of operable liposarcoma.

Daniela Greto

e23552

Inherited BRCA2 mutations and tumor hemi/homozygosity of metastatic soft tissue sarcoma in up to one-third of the 55 patients with shorter survival time.

Katsuhito Takahashi

11571

Lack of cardiac toxicity in patients treated with aldoxrubicin with doxorubicin equivalent doses beyond 1000mg/m2.

Kamalesh Kumar Sankhala

11585

Management and outcome of patients with neo-adjuvant chemotherapy (CT) in locally advanced soft-tissue sarcoma (LASTS): The Gustave Roussy experience.

Sarah Naomie Dumont

11580

Meta-analysis of prognostic parameters in primary (PAS) and secondary (SAS) breast angiosarcoma.

Ahmed Elkhanany

e23525

Multidrug analyses in cancer patients via intratumoral microdosing with CIVO: A microinjection technology for phase 0 drug investigation.

Richard Klinghoffer

e23569

Multi-institutional European phase I/II trial of trabectedin plus radiotherapy in metastaticsoft tissue sarcoma (STS) patients. A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study.

Javier Martin Broto

11544

Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa).

Andrew J. Wagner

TPS11589

Next generation sequencing (NGS) in soft tissue / bone sarcoma (STS/BS) patients.

Ofer Merimsky

e23523

Nodal involvement and survival in synovial, clear cell, angio, rhabdo, and epithelioid sarcoma.

Haotong Wang

11567

Olaratumab for the treatment of patients (pts) with advanced/metastatic soft tissue sarcoma (STS): Treatment patterns in the United States (US) during the first year post-approval.

Victor Manuel Villalobos

e23535

Optimization of trabectedin temporal protocol using mathematical PK/PD modeling.

Maeva Andriantsoa

e23553

Outcome of 91 clear cell sarcoma tumor patients: A retrospective study from the French Sarcoma Group (GSF-GETO).

Nelly Firmin

11552

Outcomes of advanced soft tissue sarcoma from dedicated medical oncology sarcoma clinic in North India and evaluation of the respective model.

Sameer Rastogi

e23561

Outcomes of intermediate-high grade retroperitoneal sarcomas.

Ruoyu Miao

e23562

PEMBROSARC combination of MK3475 and metronomic cyclophosphamide (mCP) in patients (pts) with advanced sarcomas a multicentre phase II trial with 3 new combination strategies.

Maud Toulmonde

TPS11587

Perioperative radiotherapy in patients with synovial sarcoma: An NCDB analysis.

Alicia Gingrich

e23529

Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab and nivolumab triple therapy as first line treatment of advanced soft tissue sarcoma.

Erlinda Maria Gordon

TPS11591

Phase 1b study of selinexor, a first in class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).

Eoghan Ruadh Malone

11562

Phase 1b/2 study of olaratumab plus gemcitabine and docetaxel for the treatment of advanced soft tissue sarcoma (STS) (ANNOUNCE 2): Phase 1b results.

Victor Manuel Villalobos

11542

Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.

Mrinal M. Gounder

11512

Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).

Mrinal M. Gounder

11500

Primary pulmonary sarcomas (PSRC): A comprehensive genomic profiling (CGP) study.

Sophie Beaucaire-Danel

11553

Prognostic factors of malignant paraganglioma and pheochromocytoma: A SEER database review.

Lin Mei

e23538

Prognostic role of HMG proteins in a series of 301 advanced soft tissue sarcoma patients: A Spanish Group for Sarcoma Research Study (GEIS).

Nadia Hindi

11573

Prognostic stratification using the nomogram sarculator and its impact on study results in a randomized controlled trial (RCT) for localized soft tissue sarcomas (STS): A secondary analysis of the EORTC-STBSG 62931.

Sandro Pasquali

11518

Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): Results of a phase II study (EPAZ).

Viktor Grünwald

11506

Randomized phase II trial of trofosfamide vs. adriamycin in elderly patients with previously untreated metastatic soft tissue sarcoma.

Joerg Thomas Hartmann

11507

Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial.

Axel Le Cesne

11508

Retrospective analysis of management and outcome of advanced soft tissue sarcomas (STS) with rare histology.

Atul Sharma

e23564

Retrospective analysis of patients with high-grade soft-tissue sarcoma treated with interdigitated neoadjuvant MAI chemotherapy and radiation.

Kevin Rakszawski

e23539

Safety and efficacy of irreversible electroporation for aggressive fibromatosis: Initial experience.

Kyle Maughan

e23549

Safety and efficacy of olaratumab added to doxorubicin-based combination chemotherapy in the treatment of advanced soft-tissue sarcoma (STS).

Andrea P. Espejo Freire

e23542

Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years.

Clemence Basse

11564

Short, full-dose neoadjuvant chemotherapy in localized high-risk adult soft tissue sarcomas (STS): An exploratory subgroup analysis on responding patients in a randomized controlled trial comparing 3 neoadjuvant versus 3 neoadjuvant + 2 adjuvant cycles of full dose anthracycline and ifosfamide chemotherapy at a 10yr median FU.

Silvia Stacchiotti

11558

Soft-tissue sarcomas in adults: Consultation analysis.

Rosa Haydee Vassallo

e23572

Some immunohistochemical parameters in primary and recurrent soft tissue sarcomas.

Evgeniya M. Nepomnyashchaya

e23533

SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma.

Yvonne Marie Mowery

TPS11588

Subgroup analysis of elderly patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial.

Eugenie Younger

11575

Survival impact of surgical management in reference centers for retroperitoneal sarcoma: A nationwide study of FSG-GETO and NETSARC.

Sylvie Bonvalot

11568

Systemic therapy regimen outcomes in metastatic phyllodes tumors of the breast.

Amanda Marie Parkes

11554

TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.

Vinod Ravi

TPS11590

Targeted tumor profiling and actionable somatic variants in sarcoma.

Eytan Ben Ami

11551

Targeting tumors and financial toxicity in AYAs: Exceptional response to dual immunotherapy in an uninsured young adult with soft tissue sarcoma.

Hal E. Crosswell

e23530

The efficacy and safety of Apatinib in Ewing sarcoma: A retrospective analysis.

Yitian Wang

e23522

The efficacy and safety of apatinib in patients with advanced synovial sarcoma: A single-institutional experience.

Yong Zhou

e23526

The therapeutic effect of a new method on reducing local recurrence rate of desmoid tumors involving adjacent nerves and blood vessels based on blocking-capsule theory.

Junqiang Yin

e23546

The use of apatinib combined with chemotherapy in treating soft tissue sarcoma.

Chengjuan Fan

e23524

The utility of integrative genomic profiling in sarcoma diagnosis and treatment.

Bo Zhang

e23545

Treatment of angiosarcoma with pazopanib and paclitaxel: Results of the phase II trial of the German Interdisciplinary Sarcoma Group (GISG-06 EVA) study.

Daniel Pink

11570

Upfront isolated limb perfusion (ILP) in untreated patients with unresectable non-metastatic primary soft-tissue sarcomas (STS) of the limb: The Gustave Roussy experience.

Tarek Assi

11569

Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized trial of trabectedin (T) vs. dacarbazine (D).

Gurpreet Kapoor

11513